Pace Life Sciences is honored to be participating in the upcoming Convergence Forum, for Leaders in healthcare Innovation (http://convergenceforum.com/). The event will be hosted by Future Forward, during May 10 – 11, 2018, at the beautiful Wequassett Resort & Golf Club in Chatham, on Cape Cod, Massachusetts.
Janet Wolfe, Ph.D., Founder and Senior Vice President of Wolfe Laboratories, will moderate the breakfast discussion session on Friday, May 11th, “Structuring and Managing High-Performance R&D Teams”.
According statements from Future Forward, “Each year, the Convergence Forum brings together a small group of creative and forward-thinking entrepreneurs, investors, technologists, and executives. Participants will exchange ideas with industry leaders, develop useful connections with a select group of colleagues, and lay the foundation for future business dealings. The Convergence Forum fosters real debate and discussion among audiences that are every bit as high-level as the speakers. The programs provide an opportunity for participants to make important new contacts, do business, explore important new directions in research, delve deeply into what it takes to maintain competitive advantage in a fast-changing world, and leave feeling recharged.”
For two decades, Wolfe Laboratories has provided premier product development services to global clientele. We have the world-class expertise, experience, and facilities to characterize, develop and advance novel oligonucleotide, biologic and small molecule therapeutics through the clinic. In 2017, Wolfe Laboratories became a subsidiary of Pace Analytical Life Sciences, LLC.
Our combined businesses operate four full-service laboratories located across the country providing:
- Formulation Development Services
- Product Development Services
- GMP Laboratory Testing
- Commercial Product Support
Janet Wolfe, Ph.D. is Founder and Senior Vice President of Wolfe Laboratories, Inc. Dr. Wolfe is a biopharma thought leader and has built and led development programs for small molecules and biologics across multiple therapeutic areas such as CNS, cardiovascular, metabolic diseases, immunology and oncology. Dr. Wolfe has contributed to the advancement of molecules through all stages of development and commercialization. Prior to starting Wolfe Laboratories in 1999, Dr. Wolfe was a faculty member with the Department of Pharmaceutical Sciences at the University of Tennessee, following her postdoctoral fellowship at the National Institutes of Health. Dr. Wolfe authored numerous articles and presentations, and she is the recipient of numerous awards including being named as one of New England’s Top Entrepreneurs and Innovators by the Federal Reserve Bank of Boston and one of PharmaVoice’s 100 Most Inspiring Entrepreneurs in the Life Sciences. She was awarded the Leadership Prize from Women Entrepreneurs in Science and Technology and she was named Entrepreneur to Watch by MIT Enterprise Forum. Dr. Wolfe was also recognized as Boston’s Entrepreneur of the Year by the Greater Boston Chamber of Commerce. Dr. Wolfe holds a B.S. from the University of Sciences in Philadelphia and Ph.D. in Pharmaceutical Chemistry from the University of Kansas.
About Wolfe Laboratories
Wolfe Laboratories is a premier contract research organization that provides integrated drug development solutions to the biopharmaceutical industry. Wolfe Laboratories is an essential element of the drug development ecosystem, recognized by global and virtual biopharmaceutical companies as a science-driven organization whose mission is to provide outstanding discovery and development services tailored to its clients’ needs for rational formulation development. Wolfe Laboratories integrates the critical path components of early development to ensure that programs advance while meeting rigorous scientific demands with flexibility to address dynamic challenges and aggressive timelines. Wolfe Laboratories’ vision is to improve human health, and we continue to strive towards that goal by embracing our core values of integrity, excellence and teamwork. The company has a high percentage of repeat clients, which is a testament to its long-term commitment of continual investment in its capabilities to meet biopharma’s growing demand for high quality, integrated early development services. Founded in 1999, the company is located in Woburn, Massachusetts.